Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the completion of its first export of naturally derived psilocybin to the United Kingdom, supporting a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished 5 mg psilocybin capsules manufactured at the company’s GMP facility in Princeton, British Columbia.
According to the company, the capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression. The export was authorized by Health Canada and the UK Home Office, highlighting the regulatory compliance of Optimi’s operations. The products were cultivated, extracted and manufactured in-house under Optimi’s Drug Establishment Licence, reinforcing its position as a vertically integrated GMP supplier.
This development is significant for the psychedelic industry as it demonstrates a viable pathway for Canadian companies to supply clinical trial materials to international markets. The UK has been exploring psychedelic-assisted therapies, and this export could accelerate research into psilocybin’s efficacy for mental health conditions. For Optimi, it expands its footprint beyond Australia and Canada, where its products are already accessible through regulated programs.
The company’s ability to produce both active pharmaceutical ingredients and finished dosage forms positions it as a key player in the global supply chain for psychedelic medicines. This export could pave the way for future collaborations with UK research institutions and potentially open doors to other European markets.
Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed in Australia under the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
For more information about Optimi Health, visit optimihealth.ca or optimi.net. To view the full press release, see https://ibn.fm/WLDHZ.
This article is based on content disseminated by InvestorWire, a specialized communications platform. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @IBN that provides press release syndication and corporate communications solutions. For more information, visit InvestorWire.com.
